Physician profile
Danny Luna
NPI 1407512577
$1,637.86
in general payments reported to CMS, 2019-2025
26 companies · $551 in 2025
The $551 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $304 · 2023: $356 · 2024: $427 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $223.97 | 2022-2025 | Voxzogo 1.2mg, Palynziq |
| Genzyme Corporation | $222.41 | 2022-2025 | |
| Ns Pharma, INC. | $133.57 | 2024-2025 | Viltepso |
| Mirum Pharmaceuticals, INC. | $108.13 | 2024-2025 | Cholbam, Livmarli, Cholbam |
| Ultragenyx Pharmaceutical INC. | $107.47 | 2022-2024 | Dojolvi |
| Alexion Pharmaceuticals, INC. | $103.98 | 2022-2025 | Koselugo |
| Ipsen Biopharmaceuticals, INC | $100.20 | 2022-2024 | Sohonos |
| Takeda Pharmaceuticals U.S.A., INC. | $75.94 | 2023-2025 | Vpriv |
| Soleno Therapeutics, INC. | $66.81 | 2025 | Vykat Xr |
| Amicus Therapeutics, INC. | $58.52 | 2024-2025 | Opfolda, Pombiliti |
| Immedica Pharma US, INC. | $44.77 | 2022-2023 | |
| Aucta Pharmaceuticals, INC. | $42.29 | 2025 | Motpoly Xr |
| Cycle Pharmaceuticals INC | $37.71 | 2024-2025 | Javygtor |
| Ucb, INC. | $33.89 | 2023 | |
| Ptc Therapeutics, INC. | $30.58 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $28.55 | 2025 | Gomekli |
| Kyowa Kirin, INC. | $27.71 | 2024 | Crysvita |
| Pharming Healthcare, INC. | $27.39 | 2024 | Ruconest |
| Sarepta Therapeutics, INC. | $27.33 | 2023 | |
| Acadia Pharmaceuticals INC | $25.42 | 2025 | Daybue |
| Albireo Pharma, INC. | $23.90 | 2023 | Bylvay |
| Sentynl Therapeutics, INC. | $20.94 | 2025 | Nulibry |
| Biogen, INC. | $19.47 | 2025 | Skyclarys |
| Azurity Pharmaceuticals, INC. | $18.00 | 2023 | Triptodur |
| Abiomed | $15.35 | 2024 | Impella |
| Chiesi USA, INC. | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Luna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.